TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07382427: A Phase 2, Randomized, Single-blind, Active- and Vehicle-controlled Study to Assess the Safety, Tolerability, and Efficacy of 2.4% Terbinafine Hydrochloride Topical Solution (AP4500) in Participants With Mild to Moderate

Sponsor: Onyx Axiom · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 200 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,624,000

Rescue Site Savings

+$7,005,200

Unlock Full NCT07382427 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07382427 Rescue Dossier →